Investors in Karyopharm Therapeutics Inc saw new options become available this week, for the December 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the KPTI options chain for the new December 21st contracts and identified the following put contract of particular interest.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Investors in Karyopharm Therapeutics Inc saw new options begin trading this week, for the May 2019 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 228 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Investors in Karyopharm Therapeutics Inc saw new options become available this week, for the February 2019 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Jim Cramer takes a closer look at Magellan Midstream Partners, Xylem, Boston Scientific, Karyopharm Thereapeutics, Iovance Biotherapeutics, Casella Waste Systems and more.
Jim Cramer says higher rates always trigger rotations. Here's what investors should expect.
Investors in Karyopharm Therapeutics Inc saw new options become available this week, for the June 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the KPTI options chain for the new June 15th contracts and identified one put and one call contract of particular interest.
Conference Call Scheduled for Thursday, March 15, 2018 at 8:30 a.m. ET
Investors considering a purchase of Karyopharm Therapeutics Inc stock, but cautious about paying the going market price of $14.80/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the August put at the $12.50 strike, which has a bid at the time of this writing of $1.80.
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Karyopharm Therapeutics Inc , where a total of 802 contracts have traded so far, representing approximately 80,200 underlying shares. That amounts to about 69.4% of KPTI's average daily trading volume over the past month of 115,550 shares.
Investors eyeing a purchase of Karyopharm Therapeutics Inc shares, but cautious about paying the going market price of $11.35/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the May 2018 put at the $10 strike, which has a bid at the time of this writing of $1.65.
The most recent short interest data has been released for the 10/31/2017 settlement date, which shows a 335,533 share increase in total short interest for Karyopharm Therapeutics Inc , to 2,387,184, an increase of 16.35% since 10/13/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
- Fourteen Abstracts Selected, Including Three Oral Presentations -
Conference Call Scheduled for Thursday, November 2, 2017 at 8:30 a.m. ET
